Highest-materiality recent filing
Personalis Q2 revenue up 30% to $22.4M; clinical test volume surges 199% YoY
Clinical test volume of 10,384, up 199% YoY and 33% sequentially; clinical revenue $2.6M (+442% YoY).
Personalis to be acquired by Tempus AI; $16.25 per share cash or stock election
Each Personalis share converts to $16.25 cash (if Tempus elects cash for up to 50% of shares) or Tempus shares based on exchange ratio (floor 0.3356, or $16.25/Tempus VWAP if above $48.42).
Tempus to acquire Personalis for $16.25/share, $1.5B enterprise value
Consideration of $16.25 per share, 6% premium to last close, 28% premium to 30-day VWAP.
New coverage applies to monitoring treatment response to neoadjuvant therapy in Stage II-III TNBC or HER2+ breast cancer patients.
Personalis Q1 clinical test volume +258% YoY to 7,815; secures Medicare coverage for lung cancer
Revenue $15.5M vs $20.6M YoY; clinical revenue $1.4M vs $0.3M as non-core revenue declined.
Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue
Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.
Personalis Q4 clinical test volume up 41% QoQ; Medicare coverage secured for breast cancer
Preliminary Q4 2025 revenue $17-18M; full year revenue $69-70M (2024: $84.6M).
Personalis files prospectus supplement for up to $100M at-the-market stock offering
Up to $100 million of common stock may be sold under amended ATM sales agreement with Piper Sandler and BTIG.
Personalis gets CMS revised reimbursement rates for NeXT Personal breast cancer test
CMS revised reimbursement for Personalis' NeXT Personal Dx Breast MRD test to $4,266 effective Dec 1, 2025
Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance
CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.
Personalis Q3 revenue down 44% to $14.5M; clinical tests up 364% YoY; FY guidance reduced
Revenue $14.5M (-44% YoY); net loss $21.7M ($0.24/sh) vs $39.1M ($0.64) in Q3 2024, prior year included $26M warrant expense.
Personalis receives $13.5M new task order under VA Million Veteran Program contract
New task order effective Sept 30, 2025, valued up to $13.5M subject to sample receipt and service performance.
Delivered 3,478 clinical tests in Q2 2025, a 59% sequential increase over Q1 2025.
Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029
Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.
Personalis Q1 revenue $20.6M (+6% YoY); clinical test volume up 52% sequentially
Revenue $20.6M, up 6% YoY; pharma tests/services $13.6M (+39%), population sequencing $6.7M (-29%).
FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.
Personalis reports FY2024 revenue ~$84.6M (+15% YoY), above guidance; cash ~$185M
Full year 2024 revenue of ~$84.6M, up 15% from $73.5M in 2023, above guidance range of $83-84M.
Personalis secures $50M Merck investment, extends Moderna pact, expands Tempus deal
Merck to purchase 14,044,943 shares at $3.56/share for ~$50M; closing expected Dec 19, 2024.
Personalis Q3 revenue $25.7M (+41% YoY); raises FY 2024 guidance to $83-84M
Revenue $25.7M, up 41% YoY; biopharma revenue $15.7M (+96% YoY).
New task order under VA Million Veteran Program contract effective Sept. 30, 2024, valued up to $7.5M.
Tempus exercises warrants for 9.2M shares at avg $2.00 ($18.4M) and buys 3.5M shares at $5.07 ($17.7M).
Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M
Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).
Personalis Q1 revenue $19.5M beats guidance; raises FY24 revenue outlook to $76-78M
Q1 2024 revenue $19.5M (up 3% YoY), exceeding upper-end of guidance; pharma testing revenue grew 55% to $9.8M.
Personalis Q4 revenue $19.7M (+18% YoY); FY2024 revenue guidance $73-75M
Q4 2023 revenue $19.7M (+18% YoY); FY2023 revenue $73.5M (+13% YoY).
Personalis reports Q4 revenue of $19.7M (+18% YoY); cash runway extended to Q1 2026
Preliminary Q4 revenue $19.7M, up 18% YoY from $16.7M; full-year revenue $73.5M, up 13%.
Personalis cuts up to 65 jobs, estimates $4M charge and $14M annual savings
Board approved reduction in workforce of up to 65 employees; completion expected by end of January 2024.
Personalis enters commercialization agreement with Tempus Labs for NeXT Personal Dx assay
Tempus will pay Personalis up to $12,000,000 in Market Development Fee, including a $3M activation fee.
Personalis Q3 revenue up 23% to $18.2M; raises FY2023 guidance
Revenue $18.2M (+23% YoY); net loss $29.1M, EPS -$0.60 including $5.6M impairment.
Personalis Q2 revenue $16.7M (-8% YoY); net loss $24.0M; tightens FY guidance to $70-72M
Total revenue $16.7M vs $18.2M in Q2 2022, an 8% decrease; pharma/enterprise revenue $13.7M, down 3%.
Personalis Q1 revenue $18.9M (+24% YoY); net loss $28.7M; guides Q2 rev $16-17M
Total revenue $18.9M in Q1 2023, up 24% from $15.2M in Q1 2022.
Personalis appoints Christopher Hall as CEO, Aaron Tachibana as COO, Richard Chen as EVP R&D
Aaron Tachibana appointed COO (also CFO); $515k salary, 60% bonus, option for 450k shares vesting 36 months.
Personalis reports Q4 2022 revenue $16.7M, net loss $31.1M; guides FY2023 revenue $68-72M
Q4 2022 revenue $16.7M, full year $65.0M; net loss Q4 $31.1M ($0.67/share), full year $113.3M ($2.48/share).
Personalis to cut ~30% of workforce; $3M severance, $17M savings in 2023
Reduction of up to ~30% of workforce, expected completion March 20, 2023.
Personalis prelim Q4 revenue $16.7M; FY2022 $65M, above guidance of $63-64M
FY2022 revenue from biopharma and other customers grew 42% YoY to $56.6M.
Personalis CEO John West retires; CFO Aaron Tachibana named interim CEO
CEO John West to retire as CEO and director effective Dec 31, 2022; will serve as advisor.
Personalis resolves VA MVP contract protest; stop-work order lifted
U.S. Department of Veterans Affairs MVP contract protest resolved in Personalis' favor.
Personalis Q3 revenue $14.9M; core biopharma up 73% YoY; FY2022 guidance issued
Q3 2022 revenue $14.9M vs $22.3M in Q3 2021; biopharma ex-VA revenue $14.9M (+73% YoY).
On June 13, 2023, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Kenneth Widder to the Board as a Class II director.
On June 12, 2023, Alan Colowick, a director of Personalis, Inc. (the “Company”), resigned as a member of the Company’s Board of Directors (the “Board”).
appointed (i) Aaron Tachibana as Chief Operating Officer, in addition to his role as Chief Financial Officer
The Board also appointed Mr. Hall as a member of the Board as a Class II director.
and Christopher Hall, the Company’s SVP and Head, Diagnostics Business, to serve as President, each effective December 31, 2022.
On December 9, 2022, John West, co-founder, Chief Executive Officer and member of the board of directors (the “Board”) of Personalis, Inc. (the “Company”) notified the Company of his decision to retire as Chief Executive Officer and as a director of the Company, effective as of December 31, 2022.
The Board has appointed Aaron Tachibana, the Company’s Chief Financial Officer, to serve as interim Chief Executive Officer
Jonathan MacQuitty, Ph.D., a director of Personalis, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) of his decision not to stand for reelection following the end of his current term on May 17, 2022.
The Board appointed Karin Eastham to serve as the Chair of the Board following Dr. MacQuitty’s term, effective as of May 17, 2022.
Max materiality 0.90 · Median 0.65 · Most common event earnings